Skip to main navigation

Top Menu

About Us
Our Science
Pipeline
Partnering
Investors & Media
Careers
Contact

Investors & Media

Press Releases

Year

Entasis Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

Nov 14, 2019

Entasis Therapeutics Appoints Dr. David Altarac as Chief Medical Officer

Oct 30, 2019

Entasis Therapeutics to Present at the 28th Annual Credit Suisse Healthcare Conference

Oct 29, 2019

Entasis Therapeutics Announces Multiple Presentations at ID Week 2019

Oct 03, 2019

GARDP and Entasis Therapeutics Initiate Global Phase 3 Trial of Zoliflodacin, a First-in-Class Oral Antibiotic for the Treatment of Gonorrhea

Sep 30, 2019

Entasis Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Sep 03, 2019

Entasis Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update

Aug 12, 2019

Entasis Therapeutics to Present at the Wedbush PacGrow Healthcare Conference

Aug 06, 2019

Entasis Therapeutics Appoints Dr. Howard Mayer to Board of Directors

Aug 05, 2019

Entasis Therapeutics Announces New Results Supporting Advancement of Multiple Pathogen-Targeted Antimicrobial Programs at ASM Microbe 2019

Jun 27, 2019

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Next page
Last page

Displaying 11 - 20 of 68

Toolkit

Print page
RSS Feeds
Email Alerts
Search

Investor Relations

Corporate Overview
News & Events
- Press Releases
- Events & Presentations
Stock Information
SEC Filings
Corporate Governance
Investor Resources

"Antibiotic resistance is a worldwide problem that is constantly growing. New forms of resistance can spread quickly and across continents. At Entasis, we discover and develop novel antibacterials to address the serious medical need posed by multi-drug resistant bacterial infections."

— Ruben Tommasi, Chief Scientific Officer

©2020 Entasis Therapeutics Inc.

Terms of Use | Privacy Policy